Enrica Morra
About
Enrica Morra is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine.
According to data from OpenAlex, Enrica Morra has authored 238 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Genetics, 121 papers in Hematology and 86 papers in Pathology and Forensic Medicine. Recurrent topics in Enrica Morra's work include Chronic Lymphocytic Leukemia Research (99 papers), Lymphoma Diagnosis and Treatment (85 papers) and Acute Myeloid Leukemia Research (59 papers). Enrica Morra is often cited by papers focused on Chronic Lymphocytic Leukemia Research (99 papers), Lymphoma Diagnosis and Treatment (85 papers) and Acute Myeloid Leukemia Research (59 papers). Enrica Morra collaborates with scholars based in Italy, United States and Spain. Enrica Morra's co-authors include Mario Lazzarino, Francesco Passamonti, Elisa Rumi, Roberto Cairoli, Alessandro M. Vannucchi, Francisco Cervantes, Ayalew Tefferi, Arturo Pereira, Mario Cazzola and Alessandro Beghini and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Enrica Morra
228 papers receiving 8.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Enrica Morra Italy | 46 | 5.4k | 4.5k | 2.5k | 2.4k | 1.3k | 238 | 8.7k | ||
| Mario Lazzarino Italy | 48 | 5.0k 0.9× | 5.6k 1.2× | 2.6k 1.0× | 2.6k 1.1× | 630 0.5× | 236 | 9.8k | ||
| Andrew Grigg Australia | 48 | 3.8k 0.7× | 5.0k 1.1× | 1.7k 0.7× | 1.3k 0.5× | 1.2k 0.9× | 274 | 8.8k | ||
| Luca Arcaini Italy | 49 | 4.9k 0.9× | 2.4k 0.5× | 4.2k 1.7× | 1.6k 0.7× | 1.3k 0.9× | 223 | 8.7k | ||
| Bruno Varet France | 37 | 2.6k 0.5× | 4.1k 0.9× | 1.1k 0.4× | 1.7k 0.7× | 1.4k 1.1× | 145 | 7.6k | ||
| C Rozmán Spain | 51 | 4.5k 0.8× | 5.8k 1.3× | 2.9k 1.1× | 1.6k 0.7× | 3.3k 2.5× | 309 | 11.5k | ||
| Curtis A. Hanson United States | 63 | 10.9k 2.0× | 8.7k 1.9× | 3.1k 1.2× | 5.3k 2.2× | 2.1k 1.6× | 393 | 14.7k | ||
| Fabrizio Pane Italy | 42 | 4.9k 0.9× | 6.7k 1.5× | 1.2k 0.5× | 1.9k 0.8× | 648 0.5× | 289 | 9.4k | ||
| Gregor Verhoef Belgium | 48 | 2.3k 0.4× | 3.1k 0.7× | 3.5k 1.4× | 2.2k 0.9× | 1.2k 0.9× | 187 | 9.4k | ||
| Constantine S. Tam Australia | 49 | 6.7k 1.2× | 2.6k 0.6× | 5.4k 2.1× | 1.3k 0.5× | 2.3k 1.7× | 401 | 8.8k | ||
| Sigurður Y. Kristinsson Sweden | 46 | 2.6k 0.5× | 3.9k 0.9× | 834 0.3× | 2.2k 0.9× | 594 0.4× | 142 | 6.0k |
Countries citing papers authored by Enrica Morra
Since
Specialization
Citations
This map shows the geographic impact of Enrica Morra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Enrica Morra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Enrica Morra more than expected).
Fields of papers citing papers by Enrica Morra
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Enrica Morra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Enrica Morra. The network helps show where Enrica Morra may publish in the future.
Co-authorship network of co-authors of Enrica Morra
This figure shows the co-authorship network connecting the top 25 collaborators of Enrica Morra. A scholar is included among the top collaborators of Enrica Morra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Enrica Morra. Enrica Morra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Monta, Gianluca Di, Ugo Marone, Franca Avino, et al.. (2023). Superomedial pedicle skin-reducing mastectomy in ptotic and large-sized breasts with two-stage reconstruction through transaxillary video-assisted technique: An effective surgical and anesthetic approach. Frontiers in Surgery. 9. 1040602–1040602.
2.
Olíva, Esther Natalie, Andrea Piccin, Maria Gabriella Mazzucconi, et al.. (2011). Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. Annals of Hematology. 91(4). 527–532.
3.
Tedeschi, Alessandra, Giulia Benevolo, Marzia Varettoni, et al.. (2011). Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia. Cancer. 118(2). 434–443.
4.
Visani, Giuseppe, Massimo Breccia, Antonella Gozzini, et al.. (2010). Dasatinib, even at low doses, is an effective second‐line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life‐based Italian multicenter retrospective study on 114 patients. American Journal of Hematology. 85(12). 960–963.
5.
Cirasino, Lorenzo, Anna M. Robino, Marco Cattaneo, et al.. (2009). Appropriate hospital management of adult immune thrombocytopenic purpura patients in major Italian institutions in 2000–2002: a retrospective analysis. Blood Coagulation & Fibrinolysis. 21(1). 77–84.
6.
Arcaini, Luca, Francesca Montanari, Emilio Paolo Alessandrino, et al.. (2008). Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Annals of Oncology. 19(7). 1331–1335.
7.
Tedeschi, Alessandra, Marco Montillo, Elena Strocchi, et al.. (2007). High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemotherapy and Pharmacology. 59(6). 771–779.
8.
Molica, Stefano, Marco Montillo, Doménico Ribatti, et al.. (2007). Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.. PubMed. 92(10). 1367–74.
9.
Corso, Alessandro, Luciana Barbarano, Silvia Mangiacavalli, et al.. (2007). Bortezomib with HIG-Dose Dexamethasone as First Line Therapy in Patients with Multiple Myeloma Candidates to High-Dose Therapy.. Blood. 110(11). 3595–3595.
10.
Corso, Alessandro, Silvia Mangiacavalli, Luciana Barbarano, et al.. (2007). Limited feasibility of double transplant in multiple myeloma. Cancer. 109(11). 2273–2278.
11.
Montillo, Marco, Alessandra Tedeschi, Sara Miqueleiz, et al.. (2006). Alemtuzumab As Consolidation After a Response to Fludarabine Is Effective in Purging Residual Disease in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 24(15). 2337–2342.
12.
Beghini, Alessandro, Melissa Bellini, Ivana Magnani, et al.. (2005). STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. Experimental Hematology. 33(6). 682–688.
13.
Regazzi, Mario, I Iacona, Maria Antonietta Avanzini, et al.. (2005). Pharmacokinetic Behavior of Rituximab. Therapeutic Drug Monitoring. 27(6). 785–792.
14.
Cairoli, Roberto, Alessandro Beghini, Gianpaolo Nadali, et al.. (2004). Prognostic Impact of C-Kit Mutations in Core Binding Factor-Leukemia.. Blood. 104(11). 2013–2013.
15.
Alessandrino, Emilio Paolo, Sergio Amadori, Giovanni Barosi, et al.. (2002). Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.. PubMed. 87(12). 1286–306.
16.
Beghini, Alessandro, Paolo Peterlongo, Carla B. Ripamonti, et al.. (2000). C-kit mutations in core binding factor leukemias. Blood. 95(2). 726–728.
17.
Marenco, Paola, Cristina Bianchi, Roberto Cairoli, et al.. (1996). PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation.. PubMed. 10(2). 207–12.
18.
Ferrajoli, Alessandra, A.M. Liberati, Emilio Donti, et al.. (1995). Interferon‐α plus low‐dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. European Journal Of Haematology. 55(3). 184–188.
19.
Brusamolino, Ercole, Ester Orlandi, Enrica Morra, et al.. (1994). Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy. Annals of Oncology. 5. S53–S57.
20.
Morra, Enrica, Mario Lazzarino, A Castello, et al.. (1989). Bone marrow and blood involvement by non‐Hodgkin's lymphoma: A study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation. European Journal Of Haematology. 42(5). 445–453.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mario Lazzarino Breakdown of academic impact, for papers by Andrew Grigg Breakdown of academic impact, for papers by Luca Arcaini Breakdown of academic impact, for papers by Bruno Varet Breakdown of academic impact, for papers by C Rozmán Breakdown of academic impact, for papers by Curtis A. Hanson Breakdown of academic impact, for papers by Fabrizio Pane Breakdown of academic impact, for papers by Gregor Verhoef Breakdown of academic impact, for papers by Constantine S. Tam Breakdown of academic impact, for papers by Sigurður Y. Kristinsson